Search results

This guideline covers diagnosing and managing pancreatic cancer in adults aged 18 and over. It aims to improve care by ensuring quicker and more accurate diagnosis, and by specifying the most effective treatments for people depending on how advanced their cancer is.

Result type

NICE guideline

Published

7 February 2018

Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.

Result type

Technology appraisal guidance

Published

6 September 2017

Evidence-based recommendations on venetoclax (Venclyxto) for chronic lymphocytic leukaemia in adults.

Result type

Technology appraisal guidance

Published

15 June 2022

Evidence-based recommendations on temozolomide (Temodal) for malignant glioma in children over 3 years, young people and adults.

Result type

Technology appraisal guidance

Last updated

3 March 2016

Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults.

Result type

Technology appraisal guidance

Published

9 August 2017

Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.

Result type

Technology appraisal guidance

Published

19 May 2021

This manual sets out the process for deciding how topics are identified, selected and routed for NICE guidance developed by the Centre for Health Technology Evaluation (CHTE). This includes diagnostics, highly specialised technologies, interventional procedures, medical technologies and technology appraisal guidance

Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.

Result type

Technology appraisal guidance

Published

25 January 2012

Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx; PLDH), paclitaxel, trabectedin (Yondelis) and gemcitabine. These drugs are for people with ovarian cancer that has come back some time after it was first treated.

Result type

Technology appraisal guidance

Published

27 April 2016

Find out which guidance and quality standards are awaiting development

Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.

Result type

Technology appraisal guidance

Last updated

3 March 2017

Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults.

Result type

Technology appraisal guidance

Published

11 May 2022

Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over.

Result type

Technology appraisal guidance

Published

26 October 2022

Evidence-based recommendations on prasugrel (Efient) with percutaneous coronary intervention for treating acute coronary syndromes in adults.

Result type

Technology appraisal guidance

Published

23 July 2014

Evidence-based recommendations on nivolumab (Opdivo) for advanced non-squamous non-small-cell lung cancer in adults after chemotherapy.

Result type

Technology appraisal guidance

Published

7 July 2021